Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Enrolling by invitation Phase 3 Interventional

Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus

ClinicalTrials.gov ID: NCT06475742

Public ClinicalTrials.gov record NCT06475742. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 1:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multicenter, Open-label, Single-arm, Extension Study to Evaluate the Long-term Safety and Tolerability of Cenerimod in Adult Subjects With Moderate-to-Severe Systemic Lupus Erythematosus (SLE) on Top of Background Therapy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The goal of this clinical study is to learn about the long-term safety and tolerability of cenerimod in adult patients with moderate to severe symptoms of systemic lupus erythematosus. The main questions it aims to answer are: * Whether cenerimod causes any adverse effects ('side effects') when given on top of drugs already being given for systemic lupus erythematosus. * How well cenerimod works to reduce symptoms of systemic lupus erythematosus when taken for up to 5 years. Participants taking part in this study will have already taken part in another study, where they received either cenerimod or placebo (look-alike substance containing no active drug) for 1 year. In this clinical study approximately 680 participants will receive cenerimod (on top of drugs already being given for systemic lupus erythematosus) for up to 5 years.

Study identification

NCT ID
NCT06475742
Recruitment status
Enrolling by invitation
Study type
Interventional
Phase
Phase 3
Lead sponsor
Viatris Innovation GmbH
Industry
Enrollment
680 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 29, 2024
Primary completion
Apr 30, 2028
Completion
Apr 30, 2028
Last update posted
Jul 27, 2026

2024 – 2028

United States locations

U.S. sites
14
U.S. states
5
U.S. cities
11
Facility City State ZIP Site status
University of Colorado Denver Aurora Colorado 80045
Clinical Research of West Florida, Inc. Clearwater Florida 33765
Omega Research MetroWest, LLC DeBary Florida 32713
SouthCoast Research Center, Inc. Miami Florida 33136
Allied Biomedical Research Institute Miami Florida 33155
D&H National Research Centers INC Miami Florida 33155
Professional research Center INC Miami Florida 33172
San Marcus Res Clin Inc. Miami Lakes Florida 33014
Accurate Clinical Research Inc. - Lake Charles Lake Charles Louisiana 70605
RB Wellness Clinic Las Vegas Nevada 89102
Accurate Clinical Research Inc - (Najam) Baytown Texas 77521
Novel Research LLC Bellaire Texas 77401
Accurate Clinical Research Inc. Houston Texas 77089
Sun Research San Antonio Texas 78215

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 108 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06475742, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 27, 2026 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06475742 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →